JP2012525427A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525427A5 JP2012525427A5 JP2012508734A JP2012508734A JP2012525427A5 JP 2012525427 A5 JP2012525427 A5 JP 2012525427A5 JP 2012508734 A JP2012508734 A JP 2012508734A JP 2012508734 A JP2012508734 A JP 2012508734A JP 2012525427 A5 JP2012525427 A5 JP 2012525427A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- clavulanate
- composition according
- formulation
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims 21
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 16
- 229940090805 clavulanate Drugs 0.000 claims 15
- 238000009472 formulation Methods 0.000 claims 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical group [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 claims 4
- 229960003324 clavulanic acid Drugs 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 230000004112 neuroprotection Effects 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 1
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 claims 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical group O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 229920003141 Eudragit® S 100 Polymers 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 229920003093 Methocel™ K100 LV Polymers 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 229960004977 anhydrous lactose Drugs 0.000 claims 1
- 239000006189 buccal tablet Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 230000006727 cell loss Effects 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000000905 isomalt Substances 0.000 claims 1
- 235000010439 isomalt Nutrition 0.000 claims 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 230000016273 neuron death Effects 0.000 claims 1
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000006190 sub-lingual tablet Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 239000010409 thin film Substances 0.000 claims 1
- -1 troches Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17384109P | 2009-04-29 | 2009-04-29 | |
| US61/173,841 | 2009-04-29 | ||
| PCT/US2010/032983 WO2010127125A1 (en) | 2009-04-29 | 2010-04-29 | Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525427A JP2012525427A (ja) | 2012-10-22 |
| JP2012525427A5 true JP2012525427A5 (enExample) | 2013-04-11 |
Family
ID=42261971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508734A Pending JP2012525427A (ja) | 2009-04-29 | 2010-04-29 | 神経保護および神経変性疾患の治療のためのクラブラン酸塩製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100255099A1 (enExample) |
| EP (1) | EP2424498A1 (enExample) |
| JP (1) | JP2012525427A (enExample) |
| KR (1) | KR20120012823A (enExample) |
| CN (1) | CN102413814A (enExample) |
| AU (1) | AU2010242948A1 (enExample) |
| BR (1) | BRPI1013901A2 (enExample) |
| CA (1) | CA2758029A1 (enExample) |
| IL (1) | IL215940A0 (enExample) |
| MX (1) | MX2011011459A (enExample) |
| WO (1) | WO2010127125A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0013366A (pt) * | 1999-08-16 | 2002-07-23 | Revaax Pharmaceuticals Llc | Métodos para tratar um distúrbio comportamental, um paciente humano, doença de próstata, distúrbios de ansiedade e cognitivos em um paciente humano afligido com uma condição ou disposto ao desenvolvimento de uma condição distinguida pelo menos em parte pela concentração de glutamato extracelular anormal no cérebro ou em outro tecido nervoso, distúrbio comportamental nas espécies humana, canina, felina e equina e um paciente afligido com ou disposto a desenvolver uma doença compreendendo concentrações de glutamato anormalmente elevadas em tecido neuronal ou nìveis de naaladase elevados em tecido prostático e com esclerose múltipla e para realçar a função cognitiva, formulação farmacêutica e usos de um inibidor da atividade de peptidase de uma dipeptidase ácida ligada em alfa n-acetilada e de um composto de beta-lactama |
| US6426342B2 (en) * | 1999-08-16 | 2002-07-30 | Revaax Pharmaceuticals, Llc | Use of β-lactamase inhibitors as neuroprotectants |
| MX2010004556A (es) * | 2007-10-26 | 2010-07-01 | Rexahn Pharmaceuticals Inc | Formulacion farmaceutica de acido clavulanico. |
| WO2013006808A2 (en) * | 2011-07-06 | 2013-01-10 | Rexahn Pharmaceuticals, Inc. | Clavulanic acid for treatment of restless legs syndrome |
| US8978166B2 (en) * | 2012-08-27 | 2015-03-17 | Well & David Corp. | Multi-function garment |
| KR102541110B1 (ko) | 2014-08-25 | 2023-06-08 | 에이뮨 테라퓨틱스, 인코퍼레이티드 | 난 단백질 제형 및 이의 제조 방법 |
| AU2016278846B2 (en) * | 2015-06-19 | 2021-08-05 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
| WO2020212418A1 (en) * | 2019-04-15 | 2020-10-22 | Nanologica Ab | Empty porous particles for use in treatment, prevention and/or postponement of degeneration of neurodegenerative diseases, neurons and glia. |
| TWI739220B (zh) * | 2019-11-26 | 2021-09-11 | 亞瑟瑞智科技管理顧問股份有限公司 | 包含克拉維酸與丙戊酸之組合物及其用途 |
| CN112843034B (zh) * | 2019-11-26 | 2022-08-23 | 亚瑟瑞智科技管理顾问股份有限公司 | 包含克拉维酸与丙戊酸的组合物及其用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110165A (en) * | 1974-04-20 | 1978-08-29 | Beecham Group Limited | Process for the production of clavulanic acid |
| CA1085392A (en) * | 1976-03-25 | 1980-09-09 | Masayuki Narisada | Arylmalonamido-1-oxadethiacephalosporins |
| US4127118B1 (en) * | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
| US4234579A (en) * | 1977-06-07 | 1980-11-18 | Pfizer Inc. | Penicillanic acid 1,1-dioxides as β-lactamase inhibitors |
| JO984B1 (en) * | 1977-10-11 | 1979-12-01 | بيتشام غروب ليمتد | A dry pharmaceutical compound with a suitable dosage unit for oral administration |
| NZ189022A (en) * | 1977-12-08 | 1981-11-19 | Beecham Group Ltd | Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder |
| US4273763A (en) * | 1978-01-23 | 1981-06-16 | Efamol Limited | Pharmaceutical and dietary compositions |
| US4268503A (en) * | 1978-09-14 | 1981-05-19 | Fujisawa Pharmaceutical Co., Ltd. | Antibacterial composition |
| DE3001961C2 (de) * | 1980-01-21 | 1984-08-16 | Didier Engineering Gmbh, 4300 Essen | Anströmboden für einen Wirbelschichtreaktor |
| NZ198241A (en) * | 1980-09-27 | 1983-12-16 | Beecham Group Ltd | Tablet containing amoxycillin and potassium clavulanate |
| US4594247A (en) * | 1981-12-21 | 1986-06-10 | Eli Lilly And Company | Synergistic antibacterial compositions and method of treatment of infections caused by multiple antibiotic-resistant organisms |
| JPS59104389A (ja) * | 1982-12-06 | 1984-06-16 | Shionogi & Co Ltd | オキサセファム誘導体 |
| JPS62106015A (ja) * | 1985-10-31 | 1987-05-16 | Sumitomo Pharmaceut Co Ltd | 抗痴呆薬 |
| US5256652A (en) * | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
| GB9201639D0 (en) * | 1992-01-25 | 1992-03-11 | Smithkline Beecham Plc | Pharmaceutical formulations |
| GB9215908D0 (en) * | 1992-07-27 | 1992-09-09 | Wellcome Found | Water dispersible tablets |
| US5643909A (en) * | 1993-04-19 | 1997-07-01 | Syntex (U.S.A.) Inc. | 10,11-Methanodibenzosuberane derivatives |
| JP3233407B2 (ja) * | 1993-11-06 | 2001-11-26 | 大鵬薬品工業株式会社 | 結晶性ペニシリン誘導体並びにその製造及び使用 |
| US5827537A (en) * | 1995-05-04 | 1998-10-27 | Smithkline Beecham Corporation | Pharmaceutical thermal infusion process |
| GB9515411D0 (en) * | 1995-07-27 | 1995-09-27 | Pharmacia Spa | N-(4-substituted-benzyl)-2-aminolactam derivatives |
| GB9525697D0 (en) * | 1995-12-15 | 1996-02-14 | Pharmacia Spa | Cephem derivatives |
| ES2248840T3 (es) * | 1996-02-23 | 2006-03-16 | Eli Lilly And Company | Antagonistas de vasopresina v1a no peptidilicos. |
| US5905076A (en) * | 1996-04-10 | 1999-05-18 | National Research Council Of Canada | 6-substituted amino-4-oxa-1-azabicyclo 3,2,0! heptan-7-one derivatives as cysteine protease inhibitors |
| US5795877A (en) * | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5824662A (en) * | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
| US5977090A (en) * | 1996-09-27 | 1999-11-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors |
| US5863536A (en) * | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
| US6017903A (en) * | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
| US5672592A (en) * | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
| JP2002504122A (ja) * | 1997-06-13 | 2002-02-05 | ノースウエスタン ユニバーシティー | ベータラクタマーゼ阻害剤及びその使用方法 |
| US6015809A (en) * | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
| US6177421B1 (en) * | 1999-05-04 | 2001-01-23 | Fuisz International Ltd. | Amoxicillin and clavulanate composition |
| WO2000045793A1 (en) * | 1999-02-04 | 2000-08-10 | Abbott Laboratories | Ph independent extended release pharmaceutical formulation |
| IE990159A1 (en) * | 1999-02-26 | 2000-09-20 | Fuisz Internat Ltd | Storage Stable Amoxycillin and Clavulanate Suspension Composition. |
| US6472406B1 (en) * | 1999-07-06 | 2002-10-29 | Methylgene, Inc. | Sulfonamidomethyl phosphonate inhibitors of beta-lactamase |
| BR0013366A (pt) * | 1999-08-16 | 2002-07-23 | Revaax Pharmaceuticals Llc | Métodos para tratar um distúrbio comportamental, um paciente humano, doença de próstata, distúrbios de ansiedade e cognitivos em um paciente humano afligido com uma condição ou disposto ao desenvolvimento de uma condição distinguida pelo menos em parte pela concentração de glutamato extracelular anormal no cérebro ou em outro tecido nervoso, distúrbio comportamental nas espécies humana, canina, felina e equina e um paciente afligido com ou disposto a desenvolver uma doença compreendendo concentrações de glutamato anormalmente elevadas em tecido neuronal ou nìveis de naaladase elevados em tecido prostático e com esclerose múltipla e para realçar a função cognitiva, formulação farmacêutica e usos de um inibidor da atividade de peptidase de uma dipeptidase ácida ligada em alfa n-acetilada e de um composto de beta-lactama |
| US6489319B2 (en) * | 1999-08-16 | 2002-12-03 | Revaax Pharmaceuticals, Llc | Neurotherapeutic use of carboxypeptidase inhibitors |
| US6426342B2 (en) * | 1999-08-16 | 2002-07-30 | Revaax Pharmaceuticals, Llc | Use of β-lactamase inhibitors as neuroprotectants |
| NZ519467A (en) * | 1999-12-22 | 2004-02-27 | Pharmacia Corp | Dual-release compositions of a cyclooxygenase-2- inhibitor |
| US20020013270A1 (en) * | 2000-06-05 | 2002-01-31 | Bolte Ellen R. | Method for treating a mental disorder |
| ATE286057T1 (de) * | 2000-10-20 | 2005-01-15 | Sandoz Ag | Pharmazeutische zubereitungen enthaltend clavulansäure |
| US7166626B2 (en) * | 2001-06-18 | 2007-01-23 | Revaax Pharmaceuticals, Llc | Therapeutic treatment for sexual dysfunction |
| PL371407A1 (en) * | 2002-01-10 | 2005-06-13 | Biovail Laboratories Inc. | Sedative non-benzodiazepine formulations |
| IL154370A0 (en) * | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| SI21402A (sl) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
| US7833998B2 (en) * | 2003-08-25 | 2010-11-16 | Revaax Pharmaceuticals, Llc | Oral neurotherapeutic cephalosporin sulfoxide and sulfone-containing compositions |
| PE20060489A1 (es) * | 2004-08-13 | 2006-06-19 | Schering Plough Ltd | Formulacion farmaceutica que comprende un antibiotico, un triazol y un corticosteroide |
| US20060088591A1 (en) * | 2004-10-22 | 2006-04-27 | Jinghua Yuan | Tablets from a poorly compressible substance |
| SI21912A (sl) * | 2004-12-24 | 2006-06-30 | Lek Farmacevtska Druzba D.D. | Stabilne farmacevtske oblike, ki vsebujejo amoksicilin in klavulansko kislino |
| DE102006007830A1 (de) * | 2006-02-17 | 2007-08-30 | Grünenthal GmbH | Lagerstabile orale Darreichungsform von Amoxicillin und Clavulansäure |
| CA2644911A1 (en) * | 2006-03-24 | 2007-10-04 | Panacea Biotec Ltd. | Antibiotic compositions of modified release and process of production thereof |
| US20080014257A1 (en) * | 2006-07-14 | 2008-01-17 | Par Pharmaceutical, Inc. | Oral dosage forms |
| MX2010004556A (es) * | 2007-10-26 | 2010-07-01 | Rexahn Pharmaceuticals Inc | Formulacion farmaceutica de acido clavulanico. |
-
2010
- 2010-04-29 US US12/770,304 patent/US20100255099A1/en not_active Abandoned
- 2010-04-29 MX MX2011011459A patent/MX2011011459A/es unknown
- 2010-04-29 WO PCT/US2010/032983 patent/WO2010127125A1/en not_active Ceased
- 2010-04-29 EP EP10717387A patent/EP2424498A1/en not_active Withdrawn
- 2010-04-29 AU AU2010242948A patent/AU2010242948A1/en not_active Abandoned
- 2010-04-29 CA CA2758029A patent/CA2758029A1/en not_active Abandoned
- 2010-04-29 CN CN2010800184471A patent/CN102413814A/zh active Pending
- 2010-04-29 JP JP2012508734A patent/JP2012525427A/ja active Pending
- 2010-04-29 BR BRPI1013901A patent/BRPI1013901A2/pt not_active IP Right Cessation
- 2010-04-29 KR KR1020117028280A patent/KR20120012823A/ko not_active Withdrawn
-
2011
- 2011-10-26 IL IL215940A patent/IL215940A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012525427A5 (enExample) | ||
| CA2862885C (en) | Pharmaceutical compositions containing dimethyl fumarate | |
| US20080014271A1 (en) | Novel pharmaceutical compositions comprising levetiracetam | |
| US9034860B2 (en) | Pharmaceutical composition containing low-substituted hydroxypropyl cellulose | |
| JP2017222705A5 (enExample) | ||
| US20050220877A1 (en) | Bilayer tablet comprising an antihistamine and a decongestant | |
| JP4707073B2 (ja) | アトルバスタチン経口投与用粒子状医薬組成物 | |
| NZ734446A (en) | Pharmaceutical formulations of bruton’s tyrosine kinase inhibtor | |
| US20070059360A1 (en) | Water-dispersible anti-retroviral pharmaceutical compositions | |
| CA2972179C (en) | Monomethylfumarate prodrug compositions | |
| TWI491395B (zh) | 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方 | |
| US11382866B2 (en) | Fixed dose pharmaceutical composition of valsartan and sacubitril | |
| US20110301234A1 (en) | Formulations of ladostigil tartrate | |
| AU2007255392B2 (en) | Process for making multiparticulates using a roller compactor | |
| WO2019203752A2 (en) | Combinations comprising a skeletal muscle relaxant agent and a multiple sclerosis treating agent | |
| US20110086102A1 (en) | Delayed release compositions | |
| US8653139B2 (en) | Drug substance preparations, pharmaceutical compositions and dosage forms | |
| WO2010100219A2 (en) | Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (1r)-, methanesulfonate | |
| US20090202633A1 (en) | Extended release formulations of guaifenesin | |
| US20240315978A1 (en) | Pharmaceutical compositions comprising acalabrutinib | |
| CN201179205Y (zh) | 双氯芬酸钠双释胶囊片 | |
| US20120121722A1 (en) | Atazanavir formulations | |
| WO2012172413A1 (en) | Pharmaceutical composition comprising a combination of eperisone and diclofenac and process for preparing thereof | |
| JP2009084242A (ja) | 安定性に優れた塩酸テモカプリル錠剤 | |
| WO2024084496A1 (en) | Pharmaceutical compositions comprising acalabrutinib maleate |